A translational platform for improved clinical outcome in degenerative eye diseases

At RetiPharma we have established a translational preclinical model for eye disease with ischemic pathology which provides the possibility to test neuroprotective candidate drugs with endpoints identical to daily clinical practice in human patients.

Better Clinical outcome predictions - Possible back-translation - Decreased attrition rates